

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Jiangsu Recbio Technology Co., Ltd.**

**江蘇瑞科生物技術股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2179)**

## **VOLUNTARY ANNOUNCEMENT**

### **INCLUSION OF THE COMPANY IN THE MSCI CHINA SMALL CAP INDEX**

This announcement is made by Jiangsu Recbio Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce that, MSCI announced the results of the semi-annual review of the MSCI Global Small Cap Indexes on May 12, 2023, and the Company has been selected as a constituent of the MSCI China Small Cap Index, with effect from the close of market on May 31, 2023.

The MSCI Index, a securities index compiled by Morgan Stanley Capital International (MSCI), has been widely recognized by the international financial markets as one of the most influential stock indexes in the world. It is also a benchmark index sought after by global institutional investors to optimize their investment portfolios.

Being a leading innovative vaccine company, the Group adheres to its mission of “developing the first-class vaccines to protect human health” and has built core technology platforms for innovative vaccines including novel adjuvant. The Group focuses on disease areas with significant burden to address unmet public health needs. In 2022, the Company's strategic vaccines, including its HPV 9-valent vaccine, shingles vaccine and COVID-19 vaccine, have made significant progress.

The inclusion of the Company in the MSCI China Small Cap Index signifies the Company's forthcoming entry into MSCI Global Standard Indexes, which is expected to make it attractive to the global incremental passive funds tracking such indexes and hence further enhance the liquidity of its listed securities and promote its influence in the capital market. This inclusion also reflects the global capital market's recognition of the Company by the global capital market since its listing in Hong Kong for the past year, as well as full recognition of the Company in various aspects including growth potential, overall value and corporate governance.

By order of the Board  
**Jiangsu Recbio Technology Co., Ltd.**  
**Dr. Liu Yong**  
*Chairman*

Jiangsu Province, the PRC, May 17, 2023

*As at the date of this announcement, the Board comprises Dr. LIU Yong as the chairman of the Board and an executive Director, Dr. CHEN Jianping, Mr. LI Bu and Ms. CHEN Qingqing as executive Directors, Dr. HONG Kunxue, Dr. ZHOU Hongbin, Mr. ZHANG Jiabin and Mr. HU Houwei as non-executive Directors, and Mr. LIANG Guodong, Dr. XIA Lijun, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive Directors.*